PTC Therapeutics (NASDAQ: PTCT) — Perfil da empresa, notícias e dados financeiros
PTC Therapeutics is a biopharmaceutical company focused on novel therapies for rare genetic disorders and critical illnesses.
PTC Therapeutics
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule oral therapeutics and gene therapies for rare genetic disorders and diseases with high unmet medical need. Its commercial and clinical pipeline targets severe conditions including Duchenne muscular dystrophy, spinal muscular atrophy, aromatic L-amino acid decarboxylase deficiency, phenylketonuria, Friedreich's ataxia, and Huntington's disease. The company utilizes proprietary RNA-splicing modification and ferroptosis regulation technology platforms to develop targeted disease-modifying treatments. Operations span research, clinical trial management, regulatory compliance, and commercial marketing across North America, Europe, Latin America, Asia, and the Middle East.
Resumo
Operações
Produtos e/ou serviços de PTC Therapeutics
- Duchenne Muscular Dystrophy Therapies: Commercialization of nonsense mutation restoration and corticosteroid treatments for Duchenne muscular dystrophy, generating revenues through global distribution of oral small-molecule formulations designed to slow muscle degeneration in pediatric and adult genetic patients.
- Spinal Muscular Atrophy Treatments: Production and commercialization under joint royalty agreements of oral small-molecule RNA splicing modifiers targeting the SMN2 gene to restore survival motor neuron protein levels in pediatric and adult spinal muscular atrophy.
- Gene Therapy Operations: Development and delivery of recombinant adeno-associated virus gene therapies, including direct micro-infused central nervous system treatments targeting aromatic L-amino acid decarboxylase deficiency in specialized clinical centers across North America and Europe.
- Rare Metabolic Disease Therapies: Clinical development and commercial preparation of oral sepiapterin formulations designed to reduce blood phenylalanine concentration and improve metabolic control in patients diagnosed with phenylketonuria across international regulatory jurisdictions.
- Central Nervous System & Friedreich's Ataxia Pipeline: Development of small-molecule oral therapies targeting oxidative stress, ferroptosis, and neuroinflammation pathways to mitigate central nervous system degeneration and neuromuscular impairment in conditions such as Friedreich's ataxia.
- Huntington's Disease Research: Preclinical and clinical advancement of orally bioavailable pre-mRNA splicing modifier small molecules engineered to selectively reduce mutated huntingtin protein expression in adult and pediatric patients affected by Huntington's disease.
equipe executiva do PTC Therapeutics
- Matthew B. KleinCEO & Director
- Allan Steven JacobsonCo-Founder & Independent Director
- Pierre GravierChief Financial Officer
- Neil AlmsteadChief Technical Operations Officer
- Eric PauwelsChief Business Officer
- Lee Scott GoldenExecutive VP & Chief Medical Officer
- Christine UtterSenior VP, Chief Accounting Officer & Head of People Services
- Linda Montella CarterSenior VP & Chief Information Officer
- Ellen CavaleriHead of Investor Relations
- Mark Elliott BouldingExecutive VP & Chief Legal Officer
Principais indicadores financeiros
Resultados divulgados pela PTC Therapeutics, em USD.
- Cap. de mercado
- 5,2 bi
- Receita (TTM)
- 1 bi
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- -3.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,7 bi | 856,5 mi | 682,6 mi | |
| 806,8 mi | -302,6 mi | -363,3 mi | |
| 937,8 mi | -439,5 mi | -626,6 mi | |
| 698,8 mi | -447,4 mi | -559 mi |